We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
-11.31%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$957M
AUM Growth
-$96.8M
(-9.2%)
Cap. Flow
+$96.6M
Cap. Flow
% of AUM
10.09%
Top 10 Holdings %
Top 10 Hldgs %
58.48%
Holding
64
New
21
Increased
9
Reduced
14
Closed
12
Top Buys
| 1 |
Fate Therapeutics
FATE
|
+$47.8M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$26.3M |
| 3 |
Puma Biotechnology
PBYI
|
+$24.6M |
| 4 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$17.1M |
| 5 |
AnaptysBio
ANAB
|
+$16.2M |
Top Sells
| 1 |
argenx
ARGX
|
+$32.4M |
| 2 |
KYNB
Kyntra Bio
KYNB
|
+$24.3M |
| 3 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$13.4M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
+$12.5M |
| 5 |
Kura Oncology
KURA
|
+$8.36M |
Sector Composition
| 1 | Healthcare | 92.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$450M
| $101M | 10.54% |
9,426,640
| – | – |
|
2
Xencor
XNCR
$1.11B
| $74.7M | 7.81% |
2,501,557
| – | – |
|
3
Arvinas
ARVN
$532M
| $61.6M | 6.43% |
1,528,031
+188,962
| +14% | +$8.84M |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $61.5M | 6.42% |
3,346,301
-281,296
| -8% | -$5.47M |
|
|
5
Fate Therapeutics
FATE
$350M
| $52M | 5.43% |
2,341,875
+1,890,521
| +419% | +$47.8M |
|
6
Ironwood Pharmaceuticals
IRWD
$665M
| $44.3M | 4.63% |
4,393,236
+21,828
| +0.5% | +$257K |
|
|
7
AnaptysBio
ANAB
$1.69B
| $42.9M | 4.48% |
3,036,014
+1,069,914
| +54% | +$16.2M |
|
8
Neurogene
NGNE
$790M
| $42M | 4.39% |
184,660
-11,134
| -6% | -$2.29M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $41.4M | 4.33% |
2,823,141
+668,296
| +31% | +$11.2M |
|
10
Assembly Biosciences
ASMB
$532M
| $38.4M | 4.01% |
215,890
+16,868
| +8% | +$3.62M |
|
|
11
Kura Oncology
KURA
$1B
| $34.9M | 3.65% |
3,511,690
-730,263
| -17% | -$8.36M |
|
|
KYNB
12
Kyntra Bio
KYNB
$29.8M
| $30.7M | 3.2% |
35,286
-24,403
| -41% | -$24.3M |
|
|
IPHA
13
Innate Pharma
IPHA
$170M
| $29.8M | 3.12% |
4,465,668
-79,786
| -2% | -$538K |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $27.5M | 2.87% |
357,849
+292,849
| +451% | +$26.3M |
|
|
PRVL
15
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $27.4M | 2.86% |
2,248,306
| – | – |
|
|
16
Puma Biotechnology
PBYI
$429M
| $21.4M | 2.24% |
+2,536,156
| New | +$24.6M |
|
|
MRUS
17
DELISTED
Merus
MRUS
| $20.8M | 2.17% |
1,715,962
-2,238
| -0.1% | -$35.4K |
|
|
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $18.3M | 1.91% |
1,106,180
-375,231
| -25% | -$6.8M |
|
19
Ultragenyx Pharmaceutical
RARE
$3.12B
| $16.5M | 1.72% |
371,208
+109,654
| +42% | +$5.69M |
|
|
SGMO
20
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $14.7M | 1.54% |
+2,308,079
| New | +$17.1M |
|
21
Genmab
GMAB
$17.9B
| $13.9M | 1.45% |
+653,981
| New | +$14.6M |
|
22
Acadia Pharmaceuticals
ACAD
$4.44B
| $13.7M | 1.43% |
323,889
-176,111
| -35% | -$7.26M |
|
23
Denali Therapeutics
DNLI
$3.64B
| $12.2M | 1.28% |
+698,101
| New | +$14.6M |
|
|
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
| $11.5M | 1.21% |
+1,249,611
| New | +$11.9M |
|
25
Cartesian Therapeutics
RNAC
$249M
| $11.1M | 1.16% |
153,257
| – | – |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM